Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in CancerBusiness Wire • 12/20/22
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer StudyBusiness Wire • 12/19/22
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of ResponseBusiness Wire • 12/12/22
Three-Year Follow-Up Analysis of Kite's Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 MonthsBusiness Wire • 12/12/22
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite's Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell LymphomaBusiness Wire • 12/11/22
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR AnalysisBusiness Wire • 12/11/22
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead SciencesInvestors Business Daily • 12/09/22
Arcellx flies on $325M deal with Gilead's Kite for multiple myeloma treatmentProactive Investors • 12/09/22
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple MyelomaBusiness Wire • 12/09/22
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple MyelomaPRNewsWire • 12/09/22
Gilead Sciences, Inc. (GILD) Presents at NASDAQ 47th Investor Conference (Transcript)Seeking Alpha • 12/07/22
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast CancerBusiness Wire • 12/06/22
Gilead Sciences, Inc. (GILD) Management presents at Piper Sandler Healthcare Conference (Transcript)Seeking Alpha • 11/30/22